mRNA Platform Market to Reach $129.1 Billion by 2030, Growing at a CAGR of -2.7 Percent

The global mRNA platform market is estimated to reach $129.1 billion by 2030, growing at a compound annual growth rate (CAGR) of -2.7 percent from 2024 to 2030. The market was valued at $152.0 billion in 2024. The mRNA platform has emerged as a groundbreaking innovation in biotechnology and pharmaceuticals, revolutionizing vaccine and therapeutic development.

Key Takeaways:

• The mRNA platform has the potential to address a wide range of health challenges, including infectious diseases and cancer.
• Technological advancements, such as improved delivery systems and more efficient manufacturing processes, have enhanced the scalability and efficacy of mRNA-based products.
• Regulatory support and expedited approval processes for mRNA vaccines and therapies have contributed to the rapid growth of this market.
• The market is driven by the increasing incidence of infectious diseases, advancements in mRNA technology, and significant investments in biotechnology research.
• The mRNA platform allows for the rapid redesign of vaccines and therapeutics to address new virus variants or different diseases, making it a versatile tool in precision medicine.

Statistics:

• The global mRNA platform market is projected to grow from $152.0 billion in 2024 to $129.1 billion by 2030, at a CAGR of -2.7 percent.
• The mRNA platform market is expected to reach $102.1 billion by 2030 in the COVID-19 vaccine segment, with a CAGR of -6.3 percent.
• The cancer vaccine segment is set to grow at 86.1 percent CAGR over the analysis period.
• The US market is valued at $64.5 billion in 2024 and is forecasted to grow at an impressive 0.1 percent CAGR to reach $13.8 billion by 2030.

Sources:

• ResearchAndMarkets.com's "mRNA Platform - Global Strategic Business Report"
• A release from ResearchAndMarkets.com
• Various reports and articles referenced in the original text.